Acute Ischemic Stroke Clinical Trial
Official title:
A Feasibility Study to Evaluate the Safety and Efficacy of the Cerebrovascular Interventional Procedural Control System in Treatment of Acute Ischemic Stroke
The objective of this study the first human use of a new device in treatment of acute ischemic stroke, which to evaluate the feasibility, safety, and efficacy of the Cerebrovascular Interventional Procedural Control System.
Status | Recruiting |
Enrollment | 10 |
Est. completion date | March 31, 2024 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 10 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Age 18-80. 2. Diagnosed with acute ischemic stroke. 3. Arterial occlusion in the anterior cerebral circulation that was confirmed by CTA or MRA. 4. Subject could be treated intraarterially within 8 hours after symptom onset. 5. Prestroke Modified Rankin Score = 1. 6. National Institutes of Health Stroke Scale (NIHSS) =6 and =20. 7. Patients or their legally authorised representatives provided signed, informed consent. Exclusion Criteria: 1. NCCT ASPECT score <6,or the infarct volume exceeded 1/3 of the middle cerebral artery blood supply area. 2. CT/MR Showed midline shift or cerebral hernia, and ventricle occupying effect. Intracranial hemorrhage. CTA/MRA shows carotid artery dissection, severe stenosis, or complete occlusion, which requiring carotid stent implantation during thrombectomy; Bilateral acute stroke or multiple intracranial large vessel occlusion. 3. Females who are pregnant or lactating. 4. Severe allergy to contrast agents, nickel-titanium metal or its alloys. 5. Drug-resistant hypertension (defined as sustained systolic blood pressure >185mmHg or diastolic blood pressure >110mmHg). 6. Hemorrhagic tendency (including but not limited to platelet <100*109/L, heparin treatment within 48 hours with APTT =35s, taking warfarin with an INR > 1.7). 7. Surgery or biopsy of parenchymal organs within the last 1 month 8. Any active or recent bleeding (gastrointestinal, urinary, etc.) within the last 1 month 9. Undergoing hemodialysis or peritoneal dialysis; exist of severe renal insufficiency (serum creatinine >220umol/L or 2.5mg/dl) 10. Previous intracranial hemorrhage, subarachnoid hemorrhage, brain tumor. 11. Life expectancy of less than 1 year. 12. Enrollment in another clinical trial evaluating other devices or drugs during the same period. 13. Abnormalities or diseases that the investigator considers to be excluded from the study's coverage. |
Country | Name | City | State |
---|---|---|---|
China | Beijing Tiantan Hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Hangzhou Dinova Neuroscience Technology Co., Ltd |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Good Neurological Outcome | Good clinical outcome is defined as an modified Rankin Scale (mRS) score of 0-2 at 90 days. mRS 0-2 indicates functional independence 0 - No symptoms. |
90±7 Days post-treatment | |
Primary | Technical Success | Using Cerebrovascular Interventional Procedural Control System successfully complete the catheters in placement, thrombectomy stent release, and thrombectomy system recovery, without manual conversion. | Immediately post-treatment | |
Secondary | Successful Revascularization | Achieving mTICI =2b in the target vessel within 3 passes of the cerebrovascular interventional procedural control system without the use of rescue therapy. | Immediately post-treatment | |
Secondary | Time from Groin Puncture to Reperfusion | Time from groin puncture to achievement of mTICI =2b | Immediately post-treatment | |
Secondary | Successful Recanalization Rate | Achieving mTICI =2b in the target vessel within 1 passes of the Cerebrovascular Interventional Procedural Control System without the use of rescue therapy. | Immediately post-treatment | |
Secondary | Radiation Exposure | Total fluoroscopy dose utilized during the procedure as recorded by the DSA Imaging System. | Immediately post-treatment | |
Secondary | Symptomatic Intracranial Hemorrhage | Symptomatic hemorrhage within 24 hours of procedure. Symptomatic hemorrhages is defined as any parenchymal hematoma 1 (PH1), parenchymal hematoma 2 (PH2), intraparenchymal hemorrhage remote from the ischemic field (RIH), intraventricular hemorrhage (IVH), and subarachnoid hemorrhage (SAH) associated with a worsening of National Institutes of Health Stroke Scale (NIHSS) = 4 within 24hrs. | 36 hours post-treatment | |
Secondary | Device-related Serious Adverse Events (SAEs) | Any serious adverse events related to the device, such as vessel perforation, vessel dissection, vessel rupture, and severe spasm. | Through 90 days | |
Secondary | All-cause Mortality at 90 days | Rate of mortality | Through 90 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06113848 -
Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy
|
Phase 3 | |
Completed |
NCT04069546 -
The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency
|
N/A | |
Active, not recruiting |
NCT05700097 -
Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
|
Phase 2 | |
Recruiting |
NCT06058130 -
Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis
|
N/A | |
Recruiting |
NCT04415164 -
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
|
Phase 4 | |
Recruiting |
NCT05363397 -
Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke
|
Phase 2 | |
Completed |
NCT05429658 -
Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System
|
N/A | |
Recruiting |
NCT05390580 -
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
|
N/A | |
Enrolling by invitation |
NCT05515393 -
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
|
Phase 2 | |
Active, not recruiting |
NCT05070260 -
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
|
Phase 2/Phase 3 | |
Terminated |
NCT05547412 -
Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
|
||
Completed |
NCT03366818 -
New Stent Retriever, VERSI System for AIS
|
N/A | |
Not yet recruiting |
NCT06437431 -
Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05293080 -
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
|
Phase 3 | |
Not yet recruiting |
NCT06040476 -
Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS)
|
Phase 2 | |
Completed |
NCT02223273 -
Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke)
|
N/A | |
Completed |
NCT02586233 -
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
|
Phase 1/Phase 2 | |
Terminated |
NCT01694381 -
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
|
Early Phase 1 | |
Not yet recruiting |
NCT01594190 -
Physical Activity Immediately After Acute Cerebral Ischemia
|
N/A | |
Completed |
NCT01120301 -
Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)
|
Phase 3 |